CMS’s Cell and Gene Therapy (CGT) Access Model: Implications of Outcome-based Payment Models for Pharmaceuticals
The recent FDA approval of two groundbreaking gene therapies for sickle cell disease —Casgevy and Lyfgenia—marks a significant milestone in the field, offering life-changing treatments for patients suffering from this debilitating genetic disorder.
Medicare’s Aduhelm NCD Has Implication Outside of Alzheimer’s Disease
As a third installment of our Aduhelm coverage, we look at the recently announced draft National Coverage Determination (NCD) by the Centers for Medicare and Medicaid Services (CMS).